IPO Journey
Optimi Health Corp.
IPO Date: May 20, 2026 · 10 filings tracked
Final Offer Terms
Ticker
OPTH
Exchange
Nasdaq Capital Market
Offer Price
$6.25
Shares Offered
2,400,000
Estimated Proceeds
$15.0M
Underwriters
Led by Joseph Gunnar & Co., LLC
Filing Timeline
1
F-1
September 5, 2025
- Already actively manufacturing and exporting medical-grade psilocybin and MDMA to international markets like Australia.
- Owns two state-of-the-art, 10,000-square-foot production facilities built to strict medical standards in British Columbia.
2
F-1/A
February 17, 2026
- Licensed by the Canadian government to cultivate, process, and export medical-grade psilocybin and MDMA.
- Operates as a B2B supplier, avoiding the high costs and risks associated with running clinical trials or clinics.
Changes from previous filing
- ▸ Underwriters: Joseph Gunnar & Co., LLC
3
F-1/A
March 13, 2026
- Adopts a unique 'shovel seller' B2B strategy, supplying medical-grade psychedelics (magic mushrooms and synthetic MDMA) to researchers rather than funding costly drug development.
- Backed by the billionaire family behind the athletic brand Lululemon, providing strong institutional credibility.
Changes from previous filing
- ▸ Expected offer range: $6.0 – $8.0 per share
- ▸ Shares offered: 2,142,857
- ▸ Estimated proceeds: $12M
4
F-1/A
March 24, 2026
- Operates a state-of-the-art 20,000-square-foot facility in British Columbia, Canada, producing medical-grade psilocybin and MDMA.
- Employs a 'pick-and-shovel' business model, supplying the broader psychedelic industry rather than funding expensive, risky drug trials.
Changes from previous filing
- ▸ Shares offered: 2,500,000
- ▸ Estimated proceeds: $15M
5
F-1/A
April 16, 2026
- Strategic pivot to high-profit medical-grade psilocybin and MDMA, exiting the low-margin retail supplement market.
- Already generating revenue and legally exporting prescription-grade psychedelics to Australia, Canada, and Israel.
6
F-1/A
April 21, 2026
- Transitioned to a pure-play wholesale manufacturer of medical-grade psilocybin and MDMA.
- Operates two 10,000-square-foot cultivation and manufacturing facilities in British Columbia.
7
F-1/A
April 21, 2026
- Dual-revenue model combining immediate cash flow from functional supplements with high-potential medical psilocybin supply.
- Smart 'picks and shovels' strategy positions Optimi as a licensed B2B supplier, avoiding the high costs and failure rates of drug development.
Changes from previous filing
- ▸ Ticker symbol removed
- ▸ Price range removed
8
F-1/A
April 23, 2026
- Already generating real-world revenue by legally exporting medical-grade psilocybin and MDMA to Canada and Australia
- Transitioned to a 100% pure-play psychedelic business by shutting down its natural health supplement division to boost profit margins
Changes from previous filing
- ▸ Ticker symbol: OPTH
- ▸ Exchange: Nasdaq Capital Market
- ▸ Expected offer range: $6.0 – $8.0 per share
- ▸ Shares offered: 2,500,000
- ▸ Estimated proceeds: $15M
- ▸ Underwriters: Joseph Gunnar & Co., LLC
9
F-1/A
May 19, 2026
- Acts as a pure-play supplier of medical-grade psilocybin and synthetic MDMA to global research markets.
- Avoids high drug development costs by manufacturing raw ingredients rather than running expensive clinical trials.
424B4
Final Pricing
May 20, 2026
- Actually producing and shipping physical medical-grade psilocybin and MDMA to global markets, unlike research-phase competitors.
- Secured a Nasdaq listing under the ticker 'OPTH' with an expected IPO price of US$6.25 per share.
Changes from previous filing
- ▸ Price range removed
- ▸ Final offer price: $6.25 per share
- ▸ Shares offered: 2,400,000
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.